First National Bank of Omaha Purchases New Stake in Enovis Corporation $ENOV

First National Bank of Omaha acquired a new position in shares of Enovis Corporation (NYSE:ENOV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 60,369 shares of the company’s stock, valued at approximately $1,250,000.

Several other hedge funds have also added to or reduced their stakes in ENOV. Arax Advisory Partners purchased a new position in Enovis in the fourth quarter valued at about $29,000. EverSource Wealth Advisors LLC increased its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Danske Bank A S bought a new stake in shares of Enovis in the 3rd quarter worth approximately $64,000. iSAM Funds UK Ltd bought a new stake in shares of Enovis in the 3rd quarter worth approximately $80,000. Finally, Brown Brothers Harriman & Co. purchased a new position in Enovis in the third quarter valued at approximately $90,000. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ENOV. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. BMO Capital Markets restated an “outperform” rating and issued a $30.00 target price on shares of Enovis in a research note on Friday, August 7th. Wells Fargo & Company dropped their price target on Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Finally, Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.29.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought 4,200 shares of company stock worth $92,084 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Enovis Price Performance

Shares of NYSE ENOV opened at $26.53 on Thursday. The stock has a market cap of $1.53 billion, a PE ratio of -1.38 and a beta of 1.34. Enovis Corporation has a fifty-two week low of $19.14 and a fifty-two week high of $34.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a fifty day moving average of $25.04 and a 200-day moving average of $24.11.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.